Jingtao Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jingtao Zhou has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Qingyu Li
Vanke School of Public Health, Tsinghua University, Beijing, Beijing, China
6 shared publications - Sitong Luo
Vanke School of Public Health, Tsinghua University, Beijing, China
6 shared publications - Siwen Huang
Vanke School of Public Health, Tsinghua University , Beijing
5 shared publications - Xianlong Ren
Beijing Center for Disease Prevention and Control, Beijing, Beijing, China
5 shared publications - Yuhang Zhang
Vanke School of Public Health, Tsinghua University, Beijing, Beijing, China
5 shared publications - Chi Ruan
Vanke School of Public Health, Tsinghua University, Beijing, Beijing, China
3 shared publications
Latest Publications
- Open Access
- 28 October 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e96586
Awareness of and Hypothetical Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Oral Pre-Exposure Prophylaxis Users Who Obtained the Medicine Online in China: Web-Based Cross-Sectional Study
Background: Oral pre-exposure prophylaxis (PrEP) is highly effective for HIV prevention, but its real-world impact depends on sustained adherence. Long-acting injectable cabotegravir (CAB-LA) may reduce the burden of daily or event-driven pill use. In China, many oral PrEP users obtain medication online, but little is known about their prior CAB-LA awareness or willingness to consider it. Objective: This study assessed prior CAB-LA awareness, hypothetical willingness to use CAB-LA, reported barriers and facilitators, and associated factors among oral PrEP users in China obtaining PrEP online. Methods: This cross-sectional study analyzed baseline data from the Real-world E-consumer Cohort of Oral PrEP (RECOPE), a prospective cohort in China. Participants completed a self-administered web-based questionnaire assessing prior CAB-LA awareness, hypothetical willingness after standardized CAB-LA information, sociodemographic characteristics, recent sexual behaviors and sexually transmitted infection (STI) diagnosis, and oral PrEP-related characteristics. Modified Poisson regression with robust SEs estimated prevalence ratios (PRs) and adjusted prevalence ratios (aPRs) with 95% CIs. Primary regression analyses were restricted to sexually active participants. Results: Among 621 oral PrEP users, the mean age was 29.9 (SD 6.4) years; all were assigned male sex at birth, and 608 (97.9%) identified as men. Overall, 216 of 621 (34.8%, 95% CI 31.1%‐38.6%) participants reported prior CAB-LA awareness. After receiving standardized information, 428 of 621 (68.9%, 95% CI 65.2%‐72.4%) participants expressed hypothetical willingness to use CAB-LA if it became available in China. Convenience was the most frequently reported facilitator among willing participants (395/428, 92.3%), whereas high cost was the most frequently reported barrier among those who did not express willingness (123/193, 63.7%). In adjusted analyses, event-driven PrEP users had a lower prevalence of prior CAB-LA awareness than daily PrEP users (aPR 0.66, 95% CI 0.50‐0.86), whereas participants who had switched oral PrEP regimens in the past 3 months had higher prior awareness (aPR 1.34, 95% CI 1.07‐1.68). Hypothetical willingness was more prevalent among participants reporting an STI diagnosis in the past 3 months (aPR 1.22, 95% CI 1.08‐1.39) and chemsex (aPR 1.13, 95% CI 1.01‐1.26), whereas higher PrEP-related stigma was associated with slightly lower willingness (aPR 0.99 per 1-point increase, 95% CI 0.98‐0.99). Conclusions: Among oral PrEP users in China obtaining PrEP online, prior CAB-LA awareness was limited, whereas hypothetical willingness was common after standardized information was provided. Prior awareness differed by oral PrEP regimen and recent regimen switching, whereas willingness was associated with recent STI diagnosis, chemsex, and PrEP-related stigma. Convenience was a major appeal, while cost remained an important barrier. These findings support improving access to balanced PrEP information and addressing practical barriers as long-acting PrEP becomes more widely available.
- 28 October 2026
- Published by JMIR Publications Inc. in Journal of Medical Internet Research
- Vol. 28, e96586
Open AccessAwareness of and Hypothetical Willingness to Use Long-Acting Injectable Cabotegravir and Associated Factors Among Oral Pre-Exposure Prophylaxis Users Who Obtained the Medicine Online in China: Web-Based Cross-Sectional Study
Background: Oral pre-exposure prophylaxis (PrEP) is highly effective for HIV prevention, but its real-world impact depends on sustained adherence. Long-acting injectable cabotegravir (CAB-LA) may reduce the burden of daily or event-driven pill use. In China, many oral PrEP users obtain medication online, but little is known about their prior CAB-LA awareness or willingness to consider it. Objective: This study assessed prior CAB-LA awareness, hypothetical willingness to use CAB-LA, reported barriers and facilitators, and associated factors among oral PrEP users in China obtaining PrEP online. Methods: This cross-sectional study analyzed baseline data from the Real-world E-consumer Cohort of Oral PrEP (RECOPE), a prospective cohort in China. Participants completed a self-administered web-based questionnaire assessing prior CAB-LA awareness, hypothetical willingness after standardized CAB-LA information, sociodemographic characteristics, recent sexual behaviors and sexually transmitted infection (STI) diagnosis, and oral PrEP-related characteristics. Modified Poisson regression with robust SEs estimated prevalence ratios (PRs) and adjusted prevalence ratios (aPRs) with 95% CIs. Primary regression analyses were restricted to sexually active participants. Results: Among 621 oral PrEP users, the mean age was 29.9 (SD 6.4) years; all were assigned male sex at birth, and 608 (97.9%) identified as men. Overall, 216 of 621 (34.8%, 95% CI 31.1%‐38.6%) participants reported prior CAB-LA awareness. After receiving standardized information, 428 of 621 (68.9%, 95% CI 65.2%‐72.4%) participants expressed hypothetical willingness to use CAB-LA if it became available in China. Convenience was the most frequently reported facilitator among willing participants (395/428, 92.3%), whereas high cost was the most frequently reported barrier among those who did not express willingness (123/193, 63.7%). In adjusted analyses, event-driven PrEP users had a lower prevalence of prior CAB-LA awareness than daily PrEP users (aPR 0.66, 95% CI 0.50‐0.86), whereas participants who had switched oral PrEP regimens in the past 3 months had higher prior awareness (aPR 1.34, 95% CI 1.07‐1.68). Hypothetical willingness was more prevalent among participants reporting an STI diagnosis in the past 3 months (aPR 1.22, 95% CI 1.08‐1.39) and chemsex (aPR 1.13, 95% CI 1.01‐1.26), whereas higher PrEP-related stigma was associated with slightly lower willingness (aPR 0.99 per 1-point increase, 95% CI 0.98‐0.99). Conclusions: Among oral PrEP users in China obtaining PrEP online, prior CAB-LA awareness was limited, whereas hypothetical willingness was common after standardized information was provided. Prior awareness differed by oral PrEP regimen and recent regimen switching, whereas willingness was associated with recent STI diagnosis, chemsex, and PrEP-related stigma. Convenience was a major appeal, while cost remained an important barrier. These findings support improving access to balanced PrEP information and addressing practical barriers as long-acting PrEP becomes more widely available.
- Open Access
- 29 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e92750
Evaluation of a Digital Intervention for Monitoring and Improving Medication Adherence Among Real-World e-Consumers of HIV Preexposure Prophylaxis in China: Protocol for a Randomized Controlled Trial
Background: Preexposure prophylaxis (PrEP) is a key biomedical HIV prevention strategy that relies heavily on adherence for optimal effectiveness. In China, most PrEP users purchase their medication online, making it challenging to monitor and support adherence effectively. Objective: This protocol aims to describe a digital intervention developed to monitor and improve the medication adherence of real-world e-consumers of PrEP and an evaluation plan assessing its acceptability, feasibility, and effectiveness. Methods: The Real-Time Monitoring and Precision Intervention for HIV PrEP Adherence (REMOTE) trial is a parallel-group, open-label, online-delivered, active-controlled, and stratified randomized controlled trial conducted among 430 e-consumers of PrEP (320 event-driven regimen users and 110 daily regimen users) in China. People who have purchased PrEP online, have taken PrEP in the previous 3 months, and plan to continue for the next 6 months will be stratified by regimen type and randomized into control and intervention groups at a 1:1 ratio. A WeChat-based digital platform will deliver the REMOTE intervention. The monitoring module follows ecological momentary assessment principles. The intervention design is guided by the stages of change theory, tailoring strategies to different nonadherence risks based on monitoring results. Intervention components include low-risk (health education and an artificial intelligence chatbot), medium-risk (peer forum and admonitory education), and high-risk (customized reminders and physician counseling) strategies. The control group will use a simplified platform with only real-time monitoring. The primary outcome is the proportion of participants achieving optimal adherence for 6 months, assessed via real-time monitoring and validated via surveys at baseline and the 1-, 3-, and 6-month follow-ups. Secondary outcomes include PrEP adherence knowledge, self-efficacy, risk perception, adherence barriers, stigma, and social support, measured via surveys. Intention-to-treat analysis will be conducted. Results: Funding for the study was approved in March 2024. Ethics approval for the study was granted in July 2024. The pilot trial was completed in November 2025. Baseline data collection commenced in January 2026. By February 5, 2026, recruitment and baseline data collection were completed, with 448 participants enrolled. The data have not been viewed by the research team. The intervention is currently ongoing, and the study is expected to conclude in August 2026. Results are anticipated to be published in early 2027. Conclusions: The REMOTE trial pioneers a real-time monitoring and precision intervention for e-consumers of PrEP. Leveraging technology and ecological momentary assessment, it delivers a personalized, real-time intervention that is crucial for adherence. The findings could significantly impact future HIV prevention strategies. Trial Registration: Chinese Clinical Trial Registry ChiCTR2400088278; https://www.chictr.org.cn/showproj.html?proj=236414 International Registered Report Identifier (IRRID): DERR1-10.2196/92750
- 29 June 2026
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 15, e92750
Open AccessEvaluation of a Digital Intervention for Monitoring and Improving Medication Adherence Among Real-World e-Consumers of HIV Preexposure Prophylaxis in China: Protocol for a Randomized Controlled Trial
Background: Preexposure prophylaxis (PrEP) is a key biomedical HIV prevention strategy that relies heavily on adherence for optimal effectiveness. In China, most PrEP users purchase their medication online, making it challenging to monitor and support adherence effectively. Objective: This protocol aims to describe a digital intervention developed to monitor and improve the medication adherence of real-world e-consumers of PrEP and an evaluation plan assessing its acceptability, feasibility, and effectiveness. Methods: The Real-Time Monitoring and Precision Intervention for HIV PrEP Adherence (REMOTE) trial is a parallel-group, open-label, online-delivered, active-controlled, and stratified randomized controlled trial conducted among 430 e-consumers of PrEP (320 event-driven regimen users and 110 daily regimen users) in China. People who have purchased PrEP online, have taken PrEP in the previous 3 months, and plan to continue for the next 6 months will be stratified by regimen type and randomized into control and intervention groups at a 1:1 ratio. A WeChat-based digital platform will deliver the REMOTE intervention. The monitoring module follows ecological momentary assessment principles. The intervention design is guided by the stages of change theory, tailoring strategies to different nonadherence risks based on monitoring results. Intervention components include low-risk (health education and an artificial intelligence chatbot), medium-risk (peer forum and admonitory education), and high-risk (customized reminders and physician counseling) strategies. The control group will use a simplified platform with only real-time monitoring. The primary outcome is the proportion of participants achieving optimal adherence for 6 months, assessed via real-time monitoring and validated via surveys at baseline and the 1-, 3-, and 6-month follow-ups. Secondary outcomes include PrEP adherence knowledge, self-efficacy, risk perception, adherence barriers, stigma, and social support, measured via surveys. Intention-to-treat analysis will be conducted. Results: Funding for the study was approved in March 2024. Ethics approval for the study was granted in July 2024. The pilot trial was completed in November 2025. Baseline data collection commenced in January 2026. By February 5, 2026, recruitment and baseline data collection were completed, with 448 participants enrolled. The data have not been viewed by the research team. The intervention is currently ongoing, and the study is expected to conclude in August 2026. Results are anticipated to be published in early 2027. Conclusions: The REMOTE trial pioneers a real-time monitoring and precision intervention for e-consumers of PrEP. Leveraging technology and ecological momentary assessment, it delivers a personalized, real-time intervention that is crucial for adherence. The findings could significantly impact future HIV prevention strategies. Trial Registration: Chinese Clinical Trial Registry ChiCTR2400088278; https://www.chictr.org.cn/showproj.html?proj=236414 International Registered Report Identifier (IRRID): DERR1-10.2196/92750
- Open Access
- 26 February 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (2) , e1004733
Medication adherence and its associated factors among oral pre-exposure prophylaxis (PrEP) users in China: The Real-world E-consumer Cohort of PrEP study
Background: Medication adherence is the key to success of HIV pre-exposure prophylaxis (PrEP). In China, the majority of real-world users purchase PrEP through e-commerce platforms, yet their adherence remains unaddressed. This cohort study aimed to evaluate PrEP adherence and its associated factors among e-consumers in China. Methods and findings: Eligible participants who had purchased PrEP online in the past 3 months were enrolled in the Real-world E-consumer Cohort of PrEP (RECOPE) in December 2023. Anonymous self-administered e-questionnaires were used at baseline and 1-, 3-, and 6-month follow-ups to collect data on PrEP adherence and potentially associated factors. Optimal adherence was defined as full compliance with the ‘2-1-1’ dosing protocol for event-driven (ED) users and no missed pills in the past month for daily users. Generalized linear mixed-effects models and logistic regression were fitted to identify prognostic factors of PrEP adherence. Of 877 individuals invited, 680 were eligible and 657 completed the baseline survey (response rate 96.6%). The follow-up response rate at the 1-, 3-, and 6-month timepoints was 90.1% (592/657), 82.6% (543/657), and 80.1% (526/657), respectively. Among the 621 participants who had initiated PrEP at baseline, 529 (85.2%) used the ED regimen, and 92 (14.8%) used the daily regimen. Among ED users, the prevalence of optimal adherence at the four timepoints was 41.3% (154/373), 43.1% (146/339), 45.3% (139/307), and 52.6% (160/304), respectively. Among daily users, the prevalence of optimal adherence was 83.7% (77/92), 81.4% (83/102), 87.8% (86/98), 84.3% (75/89) at each survey wave, respectively. Within this group, the mean adherence rates in the past month ranged from 97.1% to 98.7% across waves. Among ED users, older age, receptive or versatile sexual role, and higher self-efficacy were positively associated with optimal adherence, while multiple same-sex partners, chemsex, and PrEP-related stigma were negatively associated factors. Selection bias, recall bias, social desirability bias, confounding bias, and limited representativeness were the main limitations of the study. Conclusion: The study found PrEP adherence was low among ED PrEP users who account for the majority of real-world e-consumers in China. Targeted interventions are suggested to prioritize enhancing users’ understanding of medication instructions, promoting self-efficacy of maintaining adherence, and alleviating PrEP-related stigma. Additional attention should be given to ED users who have chemsex, insertive anal sex, multiple sexual partners, or a younger age.
- 26 February 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (2) , e1004733
Open AccessMedication adherence and its associated factors among oral pre-exposure prophylaxis (PrEP) users in China: The Real-world E-consumer Cohort of PrEP study
Background: Medication adherence is the key to success of HIV pre-exposure prophylaxis (PrEP). In China, the majority of real-world users purchase PrEP through e-commerce platforms, yet their adherence remains unaddressed. This cohort study aimed to evaluate PrEP adherence and its associated factors among e-consumers in China. Methods and findings: Eligible participants who had purchased PrEP online in the past 3 months were enrolled in the Real-world E-consumer Cohort of PrEP (RECOPE) in December 2023. Anonymous self-administered e-questionnaires were used at baseline and 1-, 3-, and 6-month follow-ups to collect data on PrEP adherence and potentially associated factors. Optimal adherence was defined as full compliance with the ‘2-1-1’ dosing protocol for event-driven (ED) users and no missed pills in the past month for daily users. Generalized linear mixed-effects models and logistic regression were fitted to identify prognostic factors of PrEP adherence. Of 877 individuals invited, 680 were eligible and 657 completed the baseline survey (response rate 96.6%). The follow-up response rate at the 1-, 3-, and 6-month timepoints was 90.1% (592/657), 82.6% (543/657), and 80.1% (526/657), respectively. Among the 621 participants who had initiated PrEP at baseline, 529 (85.2%) used the ED regimen, and 92 (14.8%) used the daily regimen. Among ED users, the prevalence of optimal adherence at the four timepoints was 41.3% (154/373), 43.1% (146/339), 45.3% (139/307), and 52.6% (160/304), respectively. Among daily users, the prevalence of optimal adherence was 83.7% (77/92), 81.4% (83/102), 87.8% (86/98), 84.3% (75/89) at each survey wave, respectively. Within this group, the mean adherence rates in the past month ranged from 97.1% to 98.7% across waves. Among ED users, older age, receptive or versatile sexual role, and higher self-efficacy were positively associated with optimal adherence, while multiple same-sex partners, chemsex, and PrEP-related stigma were negatively associated factors. Selection bias, recall bias, social desirability bias, confounding bias, and limited representativeness were the main limitations of the study. Conclusion: The study found PrEP adherence was low among ED PrEP users who account for the majority of real-world e-consumers in China. Targeted interventions are suggested to prioritize enhancing users’ understanding of medication instructions, promoting self-efficacy of maintaining adherence, and alleviating PrEP-related stigma. Additional attention should be given to ED users who have chemsex, insertive anal sex, multiple sexual partners, or a younger age.
- Open Access
- 3 February 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Evaluation of a Digital Intervention for Monitoring and Improving Medication Adherence Among Real-World e-Consumers of HIV Preexposure Prophylaxis in China: Protocol for a Randomized Controlled Trial (Preprint)
BACKGROUND Preexposure prophylaxis (PrEP) is a key biomedical HIV prevention strategy that relies heavily on adherence for optimal effectiveness. In China, most PrEP users purchase their medication online, making it challenging to monitor and support adherence effectively. OBJECTIVE This protocol aims to describe a digital intervention developed to monitor and improve the medication adherence of real-world e-consumers of PrEP and an evaluation plan assessing its acceptability, feasibility, and effectiveness. METHODS The Real-Time Monitoring and Precision Intervention for HIV PrEP Adherence (REMOTE) trial is a parallel-group, open-label, online-delivered, active-controlled, and stratified randomized controlled trial conducted among 430 e-consumers of PrEP (320 event-driven regimen users and 110 daily regimen users) in China. People who have purchased PrEP online, have taken PrEP in the previous 3 months, and plan to continue for the next 6 months will be stratified by regimen type and randomized into control and intervention groups at a 1:1 ratio. A WeChat-based digital platform will deliver the REMOTE intervention. The monitoring module follows ecological momentary assessment principles. The intervention design is guided by the stages of change theory, tailoring strategies to different nonadherence risks based on monitoring results. Intervention components include low-risk (health education and an artificial intelligence chatbot), medium-risk (peer forum and admonitory education), and high-risk (customized reminders and physician counseling) strategies. The control group will use a simplified platform with only real-time monitoring. The primary outcome is the proportion of participants achieving optimal adherence for 6 months, assessed via real-time monitoring and validated via surveys at baseline and the 1-, 3-, and 6-month follow-ups. Secondary outcomes include PrEP adherence knowledge, self-efficacy, risk perception, adherence barriers, stigma, and social support, measured via surveys. Intention-to-treat analysis will be conducted. RESULTS Funding for the study was approved in March 2024. Ethics approval for the study was granted in July 2024. The pilot trial was completed in November 2025. Baseline data collection commenced in January 2026. By February 5, 2026, recruitment and baseline data collection were completed, with 448 participants enrolled. The data have not been viewed by the research team. The intervention is currently ongoing, and the study is expected to conclude in August 2026. Results are anticipated to be published in early 2027. CONCLUSIONS The REMOTE trial pioneers a real-time monitoring and precision intervention for e-consumers of PrEP. Leveraging technology and ecological momentary assessment, it delivers a personalized, real-time intervention that is crucial for adherence. The findings could significantly impact future HIV prevention strategies. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR2400088278; https://www.chictr.org.cn/showproj.html?proj=236414 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/92750
- 3 February 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEvaluation of a Digital Intervention for Monitoring and Improving Medication Adherence Among Real-World e-Consumers of HIV Preexposure Prophylaxis in China: Protocol for a Randomized Controlled Trial (Preprint)
BACKGROUND Preexposure prophylaxis (PrEP) is a key biomedical HIV prevention strategy that relies heavily on adherence for optimal effectiveness. In China, most PrEP users purchase their medication online, making it challenging to monitor and support adherence effectively. OBJECTIVE This protocol aims to describe a digital intervention developed to monitor and improve the medication adherence of real-world e-consumers of PrEP and an evaluation plan assessing its acceptability, feasibility, and effectiveness. METHODS The Real-Time Monitoring and Precision Intervention for HIV PrEP Adherence (REMOTE) trial is a parallel-group, open-label, online-delivered, active-controlled, and stratified randomized controlled trial conducted among 430 e-consumers of PrEP (320 event-driven regimen users and 110 daily regimen users) in China. People who have purchased PrEP online, have taken PrEP in the previous 3 months, and plan to continue for the next 6 months will be stratified by regimen type and randomized into control and intervention groups at a 1:1 ratio. A WeChat-based digital platform will deliver the REMOTE intervention. The monitoring module follows ecological momentary assessment principles. The intervention design is guided by the stages of change theory, tailoring strategies to different nonadherence risks based on monitoring results. Intervention components include low-risk (health education and an artificial intelligence chatbot), medium-risk (peer forum and admonitory education), and high-risk (customized reminders and physician counseling) strategies. The control group will use a simplified platform with only real-time monitoring. The primary outcome is the proportion of participants achieving optimal adherence for 6 months, assessed via real-time monitoring and validated via surveys at baseline and the 1-, 3-, and 6-month follow-ups. Secondary outcomes include PrEP adherence knowledge, self-efficacy, risk perception, adherence barriers, stigma, and social support, measured via surveys. Intention-to-treat analysis will be conducted. RESULTS Funding for the study was approved in March 2024. Ethics approval for the study was granted in July 2024. The pilot trial was completed in November 2025. Baseline data collection commenced in January 2026. By February 5, 2026, recruitment and baseline data collection were completed, with 448 participants enrolled. The data have not been viewed by the research team. The intervention is currently ongoing, and the study is expected to conclude in August 2026. Results are anticipated to be published in early 2027. CONCLUSIONS The REMOTE trial pioneers a real-time monitoring and precision intervention for e-consumers of PrEP. Leveraging technology and ecological momentary assessment, it delivers a personalized, real-time intervention that is crucial for adherence. The findings could significantly impact future HIV prevention strategies. CLINICALTRIAL Chinese Clinical Trial Registry ChiCTR2400088278; https://www.chictr.org.cn/showproj.html?proj=236414 INTERNATIONAL REGISTERED REPORT DERR1-10.2196/92750
- Open Access
- 19 March 2024
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 10 (1) , e47165
Behavioral Intention of Receiving Monkeypox Vaccination and Undergoing Monkeypox Testing and the Associated Factors Among Young Men Who Have Sex With Men in China: Large Cross-Sectional Study
Background: The worldwide human monkeypox (mpox) outbreak in 2022 mainly affected men who have sex with men (MSM). In China, young men who have sex with men (YMSM) were at a potential high risk of mpox infection due to their sexual activeness and the eased COVID-19 restrictions at the end of 2022. Objective: This study aimed to investigate the behavioral intention of receiving mpox vaccination and undergoing mpox testing in 4 different scenarios and explore their associations with background and behavioral theory–related factors among Chinese YMSM. Methods: An online cross-sectional survey was conducted among YMSM aged 18-29 years from 6 representative provinces of China in September 2022. Participants recruited (recruitment rate=2918/4342, 67.2%) were asked to self-administer an anonymous questionnaire designed based on prior knowledge about mpox and classic health behavior theories. Data on the participants’ background, mpox knowledge and cognition, mpox vaccination and testing cognition, and the behavioral intention of receiving mpox vaccination and undergoing mpox testing were collected. Descriptive analysis and univariate and multivariate linear regressions were performed. Geodetector was used to measure the stratified heterogeneity of behavioral intention. Results: A total of 2493 YMSM with a mean age of 24.6 (SD 2.9) years were included. The prevalence of having a behavioral intention of receiving mpox vaccination ranged from 66.2% to 88.4% by scenario, varying in epidemic status and cost. The prevalence of having an mpox testing intention was above 90% in all scenarios regardless of the presence of symptoms and the cost. The positive factors related to vaccination intention included mpox knowledge (ba=0.060, 95% CI 0.016-0.103), perceived susceptibility of mpox (ba=0.091, 95% CI 0.035-0.146), perceived severity of mpox (ba=0.230, 95% CI 0.164-0.296), emotional distress caused by mpox (ba=0.270, 95% CI 0.160-0.380), perceived benefits of mpox vaccination (ba=0.455, 95% CI 0.411-0.498), self-efficacy of mpox vaccination (ba=0.586, 95% CI 0.504-0.668), and having 1 male sex partner (ba=0.452, 95% CI 0.098-0.806), while the negative factor was perceived barriers to vaccination (ba=–0.056, 95% CI –0.090 to –0.022). The positive factors related to testing intention were perceived severity of mpox (ba=0.283, 95% CI 0.241-0.325), perceived benefits of mpox testing (ba=0.679, 95% CI 0.636-0.721), self-efficacy of mpox testing (ba=0.195, 95% CI 0.146-0.245), having 1 male sex partner (ba=0.290, 95% CI 0.070-0.510), and having in-person gatherings with MSM (ba=0.219, 95% CI 0.072-0.366), while the negative factor was emotional distress caused by mpox (ba=–0.069, 95% CI –0.137 to –0.001). Conclusions: Among Chinese YMSM, the intention of undergoing mpox testing is optimal, while the mpox vaccination intention has room for improvement. A future national response should raise YMSM’s mpox knowledge, disseminate updated information about mpox and preventive measures, improve preventive service accessibility and privacy, and provide advice on positively coping with the associated emotional distress.
- 19 March 2024
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 10 (1) , e47165
Open AccessBehavioral Intention of Receiving Monkeypox Vaccination and Undergoing Monkeypox Testing and the Associated Factors Among Young Men Who Have Sex With Men in China: Large Cross-Sectional Study
Background: The worldwide human monkeypox (mpox) outbreak in 2022 mainly affected men who have sex with men (MSM). In China, young men who have sex with men (YMSM) were at a potential high risk of mpox infection due to their sexual activeness and the eased COVID-19 restrictions at the end of 2022. Objective: This study aimed to investigate the behavioral intention of receiving mpox vaccination and undergoing mpox testing in 4 different scenarios and explore their associations with background and behavioral theory–related factors among Chinese YMSM. Methods: An online cross-sectional survey was conducted among YMSM aged 18-29 years from 6 representative provinces of China in September 2022. Participants recruited (recruitment rate=2918/4342, 67.2%) were asked to self-administer an anonymous questionnaire designed based on prior knowledge about mpox and classic health behavior theories. Data on the participants’ background, mpox knowledge and cognition, mpox vaccination and testing cognition, and the behavioral intention of receiving mpox vaccination and undergoing mpox testing were collected. Descriptive analysis and univariate and multivariate linear regressions were performed. Geodetector was used to measure the stratified heterogeneity of behavioral intention. Results: A total of 2493 YMSM with a mean age of 24.6 (SD 2.9) years were included. The prevalence of having a behavioral intention of receiving mpox vaccination ranged from 66.2% to 88.4% by scenario, varying in epidemic status and cost. The prevalence of having an mpox testing intention was above 90% in all scenarios regardless of the presence of symptoms and the cost. The positive factors related to vaccination intention included mpox knowledge (ba=0.060, 95% CI 0.016-0.103), perceived susceptibility of mpox (ba=0.091, 95% CI 0.035-0.146), perceived severity of mpox (ba=0.230, 95% CI 0.164-0.296), emotional distress caused by mpox (ba=0.270, 95% CI 0.160-0.380), perceived benefits of mpox vaccination (ba=0.455, 95% CI 0.411-0.498), self-efficacy of mpox vaccination (ba=0.586, 95% CI 0.504-0.668), and having 1 male sex partner (ba=0.452, 95% CI 0.098-0.806), while the negative factor was perceived barriers to vaccination (ba=–0.056, 95% CI –0.090 to –0.022). The positive factors related to testing intention were perceived severity of mpox (ba=0.283, 95% CI 0.241-0.325), perceived benefits of mpox testing (ba=0.679, 95% CI 0.636-0.721), self-efficacy of mpox testing (ba=0.195, 95% CI 0.146-0.245), having 1 male sex partner (ba=0.290, 95% CI 0.070-0.510), and having in-person gatherings with MSM (ba=0.219, 95% CI 0.072-0.366), while the negative factor was emotional distress caused by mpox (ba=–0.069, 95% CI –0.137 to –0.001). Conclusions: Among Chinese YMSM, the intention of undergoing mpox testing is optimal, while the mpox vaccination intention has room for improvement. A future national response should raise YMSM’s mpox knowledge, disseminate updated information about mpox and preventive measures, improve preventive service accessibility and privacy, and provide advice on positively coping with the associated emotional distress.
- Open Access
- 12 March 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Behavioral Intention of Receiving Monkeypox Vaccination and Undergoing Monkeypox Testing and the Associated Factors Among Young Men Who Have Sex With Men in China: Large Cross-Sectional Study (Preprint)
BACKGROUND The worldwide human monkeypox (mpox) outbreak in 2022 mainly affected men who have sex with men (MSM). In China, young men who have sex with men (YMSM) were at a potential high risk of mpox infection due to their sexual activeness and the eased COVID-19 restrictions at the end of 2022. OBJECTIVE This study aimed to investigate the behavioral intention of receiving mpox vaccination and undergoing mpox testing in 4 different scenarios and explore their associations with background and behavioral theory–related factors among Chinese YMSM. METHODS An online cross-sectional survey was conducted among YMSM aged 18-29 years from 6 representative provinces of China in September 2022. Participants recruited (recruitment rate=2918/4342, 67.2%) were asked to self-administer an anonymous questionnaire designed based on prior knowledge about mpox and classic health behavior theories. Data on the participants’ background, mpox knowledge and cognition, mpox vaccination and testing cognition, and the behavioral intention of receiving mpox vaccination and undergoing mpox testing were collected. Descriptive analysis and univariate and multivariate linear regressions were performed. Geodetector was used to measure the stratified heterogeneity of behavioral intention. RESULTS A total of 2493 YMSM with a mean age of 24.6 (SD 2.9) years were included. The prevalence of having a behavioral intention of receiving mpox vaccination ranged from 66.2% to 88.4% by scenario, varying in epidemic status and cost. The prevalence of having an mpox testing intention was above 90% in all scenarios regardless of the presence of symptoms and the cost. The positive factors related to vaccination intention included mpox knowledge (ba=0.060, 95% CI 0.016-0.103), perceived susceptibility of mpox (ba=0.091, 95% CI 0.035-0.146), perceived severity of mpox (ba=0.230, 95% CI 0.164-0.296), emotional distress caused by mpox (ba=0.270, 95% CI 0.160-0.380), perceived benefits of mpox vaccination (ba=0.455, 95% CI 0.411-0.498), self-efficacy of mpox vaccination (ba=0.586, 95% CI 0.504-0.668), and having 1 male sex partner (ba=0.452, 95% CI 0.098-0.806), while the negative factor was perceived barriers to vaccination (ba=–0.056, 95% CI –0.090 to –0.022). The positive factors related to testing intention were perceived severity of mpox (ba=0.283, 95% CI 0.241-0.325), perceived benefits of mpox testing (ba=0.679, 95% CI 0.636-0.721), self-efficacy of mpox testing (ba=0.195, 95% CI 0.146-0.245), having 1 male sex partner (ba=0.290, 95% CI 0.070-0.510), and having in-person gatherings with MSM (ba=0.219, 95% CI 0.072-0.366), while the negative factor was emotional distress caused by mpox (ba=–0.069, 95% CI –0.137 to –0.001). CONCLUSIONS Among Chinese YMSM, the intention of undergoing mpox testing is optimal, while the mpox vaccination intention has room for improvement. A future national response should raise YMSM’s mpox knowledge, disseminate updated information about mpox and preventive measures, improve preventive service accessibility and privacy, and provide advice on positively coping with the associated emotional distress.
- 12 March 2023
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessBehavioral Intention of Receiving Monkeypox Vaccination and Undergoing Monkeypox Testing and the Associated Factors Among Young Men Who Have Sex With Men in China: Large Cross-Sectional Study (Preprint)
BACKGROUND The worldwide human monkeypox (mpox) outbreak in 2022 mainly affected men who have sex with men (MSM). In China, young men who have sex with men (YMSM) were at a potential high risk of mpox infection due to their sexual activeness and the eased COVID-19 restrictions at the end of 2022. OBJECTIVE This study aimed to investigate the behavioral intention of receiving mpox vaccination and undergoing mpox testing in 4 different scenarios and explore their associations with background and behavioral theory–related factors among Chinese YMSM. METHODS An online cross-sectional survey was conducted among YMSM aged 18-29 years from 6 representative provinces of China in September 2022. Participants recruited (recruitment rate=2918/4342, 67.2%) were asked to self-administer an anonymous questionnaire designed based on prior knowledge about mpox and classic health behavior theories. Data on the participants’ background, mpox knowledge and cognition, mpox vaccination and testing cognition, and the behavioral intention of receiving mpox vaccination and undergoing mpox testing were collected. Descriptive analysis and univariate and multivariate linear regressions were performed. Geodetector was used to measure the stratified heterogeneity of behavioral intention. RESULTS A total of 2493 YMSM with a mean age of 24.6 (SD 2.9) years were included. The prevalence of having a behavioral intention of receiving mpox vaccination ranged from 66.2% to 88.4% by scenario, varying in epidemic status and cost. The prevalence of having an mpox testing intention was above 90% in all scenarios regardless of the presence of symptoms and the cost. The positive factors related to vaccination intention included mpox knowledge (ba=0.060, 95% CI 0.016-0.103), perceived susceptibility of mpox (ba=0.091, 95% CI 0.035-0.146), perceived severity of mpox (ba=0.230, 95% CI 0.164-0.296), emotional distress caused by mpox (ba=0.270, 95% CI 0.160-0.380), perceived benefits of mpox vaccination (ba=0.455, 95% CI 0.411-0.498), self-efficacy of mpox vaccination (ba=0.586, 95% CI 0.504-0.668), and having 1 male sex partner (ba=0.452, 95% CI 0.098-0.806), while the negative factor was perceived barriers to vaccination (ba=–0.056, 95% CI –0.090 to –0.022). The positive factors related to testing intention were perceived severity of mpox (ba=0.283, 95% CI 0.241-0.325), perceived benefits of mpox testing (ba=0.679, 95% CI 0.636-0.721), self-efficacy of mpox testing (ba=0.195, 95% CI 0.146-0.245), having 1 male sex partner (ba=0.290, 95% CI 0.070-0.510), and having in-person gatherings with MSM (ba=0.219, 95% CI 0.072-0.366), while the negative factor was emotional distress caused by mpox (ba=–0.069, 95% CI –0.137 to –0.001). CONCLUSIONS Among Chinese YMSM, the intention of undergoing mpox testing is optimal, while the mpox vaccination intention has room for improvement. A future national response should raise YMSM’s mpox knowledge, disseminate updated information about mpox and preventive measures, improve preventive service accessibility and privacy, and provide advice on positively coping with the associated emotional distress.